Novartis partner Durect registers a PhIII pain drug flop, biotech’s shares crater
Eighteen months after the FDA ordered Durect$DRRX to amend its Phase III study of its pain drug posimir, the biotech is reporting that the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
